Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL9748312 | 0.98 | CYP3A4 (0.50) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL9748375 | 0.98 | CYP3A4 (0.49) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL9748438 | 0.88 | CYP3A4 (0.66) | CYP3A4RAB9AMAPK1KDM4EMEN1 | |
| Oxalic Acid SCHEMBL7996063 | 0.85 | CYP3A4 (0.64) | CYP3A4RAB9AMAPK1KDM4EMEN1 | |
| Oxalic Acid SCHEMBL9747718 | 0.85 | CYP3A4 (0.63) | CYP3A4RAB9ANPC1SMN1; SMN2MAPK1 | |
| Oxalic Acid SCHEMBL9747799 | 0.85 | CYP3A4 (0.62) | CYP3A4RAB9ANPC1SMN1; SMN2MAPK1 | |
| Levosemotiadil SCHEMBL678293 | 0.83 | CYP3A4 (0.68) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 | |
| Semotiadil SCHEMBL678676 | 0.83 | CYP3A4 (0.68) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 | |
| Semotiadil SCHEMBL80715 | 0.83 | CYP3A4 (0.68) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 | |
| Semotiadil SCHEMBL29396077 | 0.83 | CYP3A4 (0.68) | CYP3A4RAB9AMAOBNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0237573-B1 | NOVEL BENZOTHIAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4786635-A | THERAPEUTIC AGENTS FOR CIRCULATORY DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1988-11-22 | — | — | US | disclosed |
| EP-0237573-A1 | NOVEL BENZOTHIAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1987-09-23 | — | — | EP | disclosed |